Totally Keyboards has relaunched, you can still continue to use the old site at this time but we will be closing it down in the future. Click here to head over to the NEW TK Site.
Join site | Forgot
Welcome, Guest
Username Password: Remember me
  • Page:
  • 1

TOPIC: Acute vasodilator action of pindolol in humans.

Acute vasodilator action of pindolol in humans. 1 year, 2 months ago #3924

  • freemexy
  • Platinum Boarder
  • Posts: 568
  • Karma: 0
Acute vasodilator action of pindolol in humans.

The local hemodynamic effect of pindolol, a nonselective beta-blocker with intrinsic sympathomimetic activity, was investigated in 17 healthy volunteers. Changes in forearm blood flow (FBF) in response to infusion of drugs into the brachial artery were measured by plethysmography. Pindolol increased FBF dose dependently to a maximal value of 62 +/- 8% (mean +/- SEM, p less than 0.001) without inducing changes in heart rate or blood pressure. For a single dose of pindolol the maximal effect on FBF was seen after approximately 4 minutes of infusion, and this effect persisted for at least 12 minutes after the infusion. wisepoqder Pindolol powder
The pindolol-induced increase in FBF was reduced by concomitant infusion of propranolol (p less than 0.001). Intra-arterial infusion of practolol did not influence FBF. No significant influence of pindolol was found on the vasoconstriction induced by the alpha 1-adrenergic receptor agonist methoxamine, the alpha 2-adrenergic receptor agonist BHT-933, or angiotensin II. Measurement of plasma pindolol concentrations in the venous effluent of the forearm suggested that vasodilatation occurred at drug levels within the therapeutic range. These results indicate that the beta-blocker pindolol has vasodilatory properties owing to stimulation of vascular beta 2-adrenergic receptors and that this effect may be of therapeutic relevance.
The drug pindolol was proven to reduce alcohol consumption, in particularly binge drinking, according to the study from Queensland University of technology researchers. The good news is, if the drug is proved successful following the completion of human clinical trials, then it already has Food and Drug Administration (FDA) approval. Neuroscientist Professor Selena Bartlet, from the tnstitute of Health and Biomedical Innovation, said it would provide an inexpensive approach to treating alcohol dependence.

‘Drugs currently used for AUDs (alcohol use disorders) – acamprosate, naltrexone and disulfiram – have limited success – so this is a ground-breaking development with enormous potential. ‘In an internationally-significant breakthrough, our study showed pindolol was able to reduce ethanol/alcohol consumption, particularly in relation to binge drinking, a key behaviour observed in human alcohol dependence.’
  • Page:
  • 1